Please login to the form below

Not currently logged in
Email:
Password:

cost and value

This page shows the latest cost and value news and features for those working in and with pharma, biotech and healthcare.

Is Orkambi deal close? Vertex meets again today with NHS England

Is Orkambi deal close? Vertex meets again today with NHS England

It has been three years since Orkambi was approved in Europe, but for much of that time Vertex has been at loggerheads with England’s cost effectiveness watchdog NICE and NHS ... Both sides have blamed the other for inflexibility on the cost and value

Latest news

  • Optimism on Orkambi in England as talks to resume Optimism on Orkambi in England as talks to resume

    During the health and select committee inquiry held last week, NHS England and NICE and Vertex blamed each other for inflexibility on the cost and value of the drug, which has ... And please do not forget those who desperately need #Brineura #Kuvan and

  • Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

    cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... By contrast, Leiden claimed Vertex merely wanted NICE to factor in more direct savings to healthcare cost – such as greatly reduced hospitalisation

  • How to pay for very high cost, curative drugs? ICER and NICE put their heads together How to pay for very high cost, curative drugs? ICER and NICE put their heads together

    Three HTA bodies seek answers to future value models. When Novartis’ hinted last year that its SMA gene therapy Zolgensma could cost $4m per patient, it put healthcare systems on notice ... handle. Now three health technology assessment (HTA)

  • Profit: the ugly, dirty truth? Profit: the ugly, dirty truth?

    The price of new medicines is commonly defended by companies by reflecting on the need for return on the cost of discovery and development, and the value these new medicines will ... Medicine spending needs to be put into perspective. It is also notable

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    But Meindert Boysen told a London meeting conversations between the cost-effectiveness watchdog and the industry about value need to be conducted in a more open manner. ... all. Our job is to make sure we buy value. And if that value is increasing, then

More from news
Approximately 1 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • The evolution of marketing – the Amgen way The evolution of marketing – the Amgen way

    We are committed to exploring and pursuing healthcare solutions that reinvent and even disrupt the current approaches to healthcare access, cost, value and innovation. ... Commercial functions have been evolving and, beyond traditional marketing, teams

  • Changing direction: adapting to a rapidly-evolving environment Changing direction: adapting to a rapidly-evolving environment

    However, against an industry-wide backdrop of colossal cost structures and deeply embedded business practices, developing agility is no easy feat. ... As the pressure to deliver shareholder value intensifies and cost leadership emerges as a source of

  • The Orkambi blame game The Orkambi blame game

    on the cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... a far more cost-effective deal with Vertex on its CF portfolio.

  • Seismic shifts: Hepatitis C and payers Seismic shifts: Hepatitis C and payers

    But are we, as an industry, doing enough to support politicians, payers and the public in understanding both the value behind the acquisition cost and how medicines can be afforded when ... IMS Health market data shows that in the next 5 years 40% of

  • Determining value to withstand all tests Determining value to withstand all tests

    It's no longer enough for us to be ready to respond to value and pricing questions, we need to proactively communicate, engage and educate, and not just with decision makers. ... Ensuring a truly cross-functional approach to the creation of a value

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • HSJ Partnership Awards 2019 shortlist announced HSJ Partnership Awards 2019 shortlist announced

    The Partnership Awards celebrate the people and businesses promoting joint working and supplier innovation to deliver better and more cost-effective patient care. ... Value Awards. Excellence in procurement, financial management and driving value helps

  • Healthcare excellence celebrated at 2018 HSJ Awards

    the best in value and effectiveness. ... Value Awards. Excellence in procurement, financial management and driving value helps the NHS serve patients.

  • HSJ Awards Finalists Announced

    for patients, while ensuring the best in value and effectiveness. ... Value Awards Excellence in procurement, financial management and driving value helps the NHS serve patients.

  • A4P Bio Consulting Ltd

    As experts in biomarkers, bioanalysis, pharmacokinetics, logistics and quality systems management A4P deliver scientifically robust, regulatory compliant, cost effective and value added solutions for the global life sciences sector.

  • How can pharma engage with Accountable Care Systems?

    Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain how pharma can add value across care pathways. ... As a result, cost-based value propositions that guarantee outcomes and work to achieve them through enhanced compliance and concordance will

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics